Penumbra Inc (PEN) Stock Price, Quote & News

Company Profile

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under...

Industry: Medical Devices

Sector: Healthcare

Phone: 510 748 3200

Website: www.penumbrainc.com

Address:

One Penumbra Place, Alameda, United States

StockAnalyst_SA Jan. 7 at 12:00 PM

🔋 $TE | Still Too Cheap Full analysis here! It's free👉 @StockAnalyst_SA (No noise !!) 📈 Key info: 2025 Q1-Q3 G1 Dallas commissioned 1.2–1.6 GW modules Revenue $3M → $400M TTM 2025 Q4 Ramp to 2.6–3.0 GW FY output Q4 revenue > Q1-Q3 combined 2026 G1 ramp → 5 GW modules 60% supply contracted G2 (2.1 GW) under construction → SOP Q4 2026 💹 Valuation: Current P/S 2.9x After Q4 <1.4x After 2026 <1x 💡 Takeaway: Fundamentals still catching up → TE remains cheap GLTA / NFA — Not financial advice $REXR $DINO $PEN $RKLB

0 · Reply

StockAnalyst_SA Jan. 7 at 11:55 AM

🚁 $EH | China Discount Opportunity Full analysis here! It's free👉 @StockAnalyst_SA (No noise !!) 📌 Key info: EHang flew air chief over capital of 72M-pop country Announced 100 eVTOLs + commercial ops ASAP Video released → stock still flat ⚡ Market note: Joby / Archer → likely instant moon China discount extreme → huge opportunity 💡 Takeaway: Major catalyst done, market underestimates → potential upside GLTA / NFA — Not financial advice $REXR $DINO $PEN $GME

0 · Reply

BillionerOfKing Jan. 7 at 4:53 AM

$PEN Current Stock Price: $317.03 Contracts to trade: $320 PEN Jan 16 2026 Call Entry: $5.00 Exit: $8.20 ROI: 64% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

ZacksResearch Dec. 26 at 12:42 PM

$PEN up 31.3% in a year — what's fueling this growth? 🚀 📈 Robust portfolio expansion with a focus on thrombectomy tech 🌍 International sales up 6.6% as global efforts gain traction 🔄 Zacks Rank #3 and consistent earnings surprises (11.6% avg.) Opportunity assessment here 👉 https://www.zacks.com/stock/news/2808996/reasons-to-retain-penumbra-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2808996-body-26351&ADID=SYND_STOCKTWITS_TWEET_2_2808996_BODY_26351

0 · Reply

ZacksResearch Dec. 26 at 11:42 AM

Why $PEN still deserves a spot in your portfolio — for now 🧠 PEN is gaining momentum from its expanding thrombectomy portfolio and a growing international footprint, even as FX headwinds and broader macro pressures remain key risks. See the full risk/reward setup here 👉 https://www.zacks.com/stock/news/2808996/reasons-to-retain-penumbra-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2808996-teaser-26350&ADID=SYND_STOCKTWITS_TWEET_2_2808996_TEASER_26350

0 · Reply

OfficialStocktwitsUser Dec. 24 at 8:03 PM

$PEN RSI: 66.02, MACD: 10.8720 Vol: 11.29, MA20: 303.42, MA50: 277.33 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Thelonius_Stonk Dec. 21 at 12:43 PM

$PEN 👀

0 · Reply

JarvisFlow Dec. 18 at 3:55 PM

Truist Securities updates rating for Penumbra ( $PEN ) to Buy, target set at 312 → 370.

0 · Reply

erevnon Dec. 18 at 2:47 PM

JP Morgan upgrades Penumbra $PEN from Neutral to Overweight and raises the price target from $275 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

JarvisFlow Dec. 18 at 1:05 PM

JP Morgan updates rating for Penumbra ( $PEN ) to Overweight, target set at 275 → 370.

0 · Reply

Penumbra, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 3, 2025, 12:33 PM EST - 5 weeks ago

Penumbra, Inc. (PEN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Nov 19, 2025, 4:30 PM EST - 7 weeks ago

Penumbra, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 5, 2025, 7:31 PM EST - 2 months ago

Penumbra, Inc. (PEN) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 4:05 PM EST - 2 months ago

Penumbra, Inc. Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 3:00 PM EST - 2 months ago

Latest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary Embolism

Oct 27, 2025, 9:00 AM EDT - 2 months ago

Landmark STORM-PE Randomized Controlled Trial Finds Computer Assisted Vacuum Thrombectomy (CAVT) with Anticoagulation Superior to Traditional Anticoagulation Treatment for Pulmonary Embolism

Oct 27, 2025, 5:37 AM EDT - 2 months ago

Penumbra, Inc. (PEN) Presents at Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 Transcript

Oct 8, 2025, 4:30 PM EDT - 3 months ago

Penumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025

Sep 9, 2025, 4:44 PM EDT - 4 months ago

Penumbra, Inc. (PEN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 9:00 AM EDT - 4 months ago

New Survey Shows Management of Blood Clots is Inconsistent, Even for Patients with the Same Risk Profile

Sep 3, 2025, 12:28 PM EDT - 4 months ago

Penumbra, Inc. (PEN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Aug 27, 2025, 9:00 AM EDT - 4 months ago

Penumbra, Inc. Names Shruthi Narayan as Company President

Aug 20, 2025, 4:30 PM EDT - 5 months ago

Penumbra, Inc. to Present at Upcoming Investor Conferences

Aug 7, 2025, 9:45 PM EDT - 5 months ago

Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025

ACLX BSX EW EXAS GH ISRG LLY

Jul 30, 2025, 4:30 PM EDT - 5 months ago

Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 29, 2025, 9:04 PM EDT - 5 months ago

Penumbra, Inc. (PEN) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 4:05 PM EDT - 5 months ago

Penumbra, Inc. Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 9:57 AM EDT - 6 months ago

Five years after COVID, pharma shares languish in US policy limbo

ABBV ABT ALNY AZN EW LLY MRK

Jul 1, 2025, 4:30 PM EDT - 6 months ago

Penumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025

Jun 26, 2025, 6:00 AM EDT - 7 months ago

Penumbra: AI Meets Aspiration - Why The Stock Is A Structural Winner

Jun 16, 2025, 9:00 AM EDT - 7 months ago

Penumbra, Inc. Announces Completion of Enrollment for Landmark STORM-PE Randomized Controlled Trial

Jun 5, 2025, 9:00 AM EDT - 7 months ago

Penumbra Introduces the Ruby® XL System - the Longest, Largest, and Softest Coil on the Market for Vascular Embolization

Apr 29, 2025, 4:30 PM EDT - 9 months ago

Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference

Apr 29, 2025, 11:45 AM EDT - 9 months ago

Baron Health Care Fund Q1 2025 Top Net Purchases And Sales

ACLX ISRG MASI MCK NTRA TMO UNH

Apr 24, 2025, 3:27 PM EDT - 9 months ago

Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst

Apr 23, 2025, 8:15 PM EDT - 9 months ago

Penumbra, Inc. (PEN) Q1 2025 Earnings Call Transcript

Apr 23, 2025, 4:05 PM EDT - 9 months ago

Penumbra, Inc. Reports First Quarter 2025 Financial Results

Apr 3, 2025, 4:30 PM EDT - 9 months ago

Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025

Apr 2, 2025, 9:00 AM EDT - 10 months ago

Seven New Data Sets Demonstrate Penumbra's Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits

Feb 21, 2025, 4:05 PM EST - 11 months ago

Penumbra, Inc. Announces Don Kassing will Retire from Board of Directors

Feb 19, 2025, 4:03 PM EST - 11 months ago

Stroke Device Maker Penumbra Stock Surges On Earnings Beat, Analysts Boost Price Forecasts After Upbeat 2025 Outlook

Feb 18, 2025, 11:04 PM EST - 11 months ago

Penumbra, Inc. (PEN) Q4 2024 Earnings Call Transcript

Feb 18, 2025, 4:05 PM EST - 11 months ago

Penumbra, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

Jan 21, 2025, 4:30 PM EST - 1 year ago

Penumbra, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for February 18, 2025

Dec 30, 2024, 4:30 PM EST - 1 year ago

Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 17, 2024, 11:03 AM EST - 1 year ago

Penumbra Is Poised For Growth As Blood Clot Awareness Rises: Analyst

Nov 20, 2024, 4:30 PM EST - 1 year ago

Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 5, 2024, 9:00 AM EST - 1 year ago

New Late Breaking Data Show Patients Treated with Penumbra's Computer Assisted Vacuum Thrombectomy Technology for Pulmonary Embolism Experience Shorter Hospital Stays and Fewer Complications Compared to Other Treatment Options

Oct 30, 2024, 11:45 PM EDT - 1 year ago

Penumbra, Inc. (PEN) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 4:05 PM EDT - 1 year ago

Penumbra, Inc. Reports Third Quarter 2024 Financial Results

Oct 14, 2024, 9:00 AM EDT - 1 year ago

Penumbra, Inc. Announces Completion of THUNDER IDE Study Enrollment for Acute Ischemic Stroke

Oct 2, 2024, 4:30 PM EDT - 1 year ago

Penumbra, Inc. Schedules Third Quarter 2024 Earnings Release and Conference Call for October 30, 2024

Sep 16, 2024, 3:00 AM EDT - 1 year ago

Penumbra Receives CE Mark for Computer Assisted Vacuum Thrombectomy Technologies - Lightning Flash™ 2.0 and Lightning Bolt™ 7 - in Europe

Aug 27, 2024, 4:30 PM EDT - 1 year ago

Penumbra, Inc. to Present at the Baird Global Healthcare Conference

Aug 21, 2024, 4:30 PM EDT - 1 year ago

Penumbra, Inc. to Present at the Wells Fargo Healthcare Conference

Aug 19, 2024, 9:28 PM EDT - 1 year ago

Penumbra: Growth In Its Thrombectomy Portfolio Should Lead To Strong Earnings

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Penumbra, Inc. Announces $200 Million Share Repurchase Authorization

StockAnalyst_SA Jan. 7 at 12:00 PM

0 · Reply

StockAnalyst_SA Jan. 7 at 11:55 AM

0 · Reply

BillionerOfKing Jan. 7 at 4:53 AM

0 · Reply

ZacksResearch Dec. 26 at 12:42 PM

0 · Reply

ZacksResearch Dec. 26 at 11:42 AM

0 · Reply

OfficialStocktwitsUser Dec. 24 at 8:03 PM

0 · Reply

Thelonius_Stonk Dec. 21 at 12:43 PM

$PEN 👀

0 · Reply

JarvisFlow Dec. 18 at 3:55 PM

Truist Securities updates rating for Penumbra ( $PEN ) to Buy, target set at 312 → 370.

0 · Reply

erevnon Dec. 18 at 2:47 PM

JP Morgan upgrades Penumbra $PEN from Neutral to Overweight and raises the price target from $275 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

JarvisFlow Dec. 18 at 1:05 PM

JP Morgan updates rating for Penumbra ( $PEN ) to Overweight, target set at 275 → 370.

0 · Reply

JarvisFlow Dec. 17 at 8:02 PM

Canaccord Genuity updates rating for Penumbra ( $PEN ) to Buy, target set at 355 → 359.

0 · Reply

JarvisFlow Dec. 17 at 3:05 PM

Needham updates rating for Penumbra ( $PEN ) to Buy, target set at 326 → 388.

0 · Reply

JarvisFlow Dec. 11 at 2:03 PM

Citigroup has updated their rating for Penumbra ( $PEN ) to Buy with a price target of 350.

0 · Reply

BillionerOfKing Dec. 4 at 2:37 AM

$PEN Current Stock Price: $285.75 Contracts to trade: $290 PEN Dec 19 2025 Call Entry: $4.40 Exit: $8.69 ROI: 97% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Doozio Nov. 30 at 12:06 AM

failed monthly Mac D 🐑! Use that $PEN n ✍️ it down. Or ⬆️. 🐒🍌🧠⏰♾️

0 · Reply

Wigglyick Nov. 29 at 11:10 PM

$PEN Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA. Penumbra popped after it’s Q3 ER. On the weekly it’s golden crossed and the daily is heading that way. They gave good guidance and are still in a long term uptrend. No position.

1 · Reply

123rs123 Nov. 27 at 4:48 AM

$PEN Called it. I love this company but unfortunately as soon as it touches 300, it’s a short. I have sold my position and initiated a short at 301

1 · Reply

Looking4Bargain Nov. 18 at 2:00 PM

$PEN this will hit $320 next earnings - no stopping now.

0 · Reply

SuperGreenToday Nov. 13 at 3:37 PM

$PEN Share Price: $275.74 Contract Selected: Apr 17, 2026 $280 Calls Buy Zone: $18.79 – $23.21 Target Zone: $35.66 – $43.59 Potential Upside: 79% ROI Time to Expiration: 154 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

ZacksResearch Nov. 11 at 1:57 PM

$PEN keeps climbing! 🚀 Q3 adjusted EPS of 97 cents beat estimates by 7.78%, and revenues surged 17.8% year over year on a reported basis, propelling the stock up 20% since the announcement on Nov. 5. Impressive margin expansions and strong product sales are driving the momentum. 📈 Discover the full story here 👉 https://www.zacks.com/stock/news/2789089/penumbra-stock-up-post-q3-earnings-revenue-beat-margins-expand?cid=sm-stocktwits-2-2789089-body-20424&ADID=SYND_STOCKTWITS_TWEET_2_2789089_BODY_20424

0 · Reply

ZacksResearch Nov. 11 at 12:57 PM

$PEN surges after strong Q3 beat 🔥 Earnings and revenue both topped estimates, and the company’s margins expanded — signaling solid operational strength this quarter. See what’s driving the move higher 👉 https://www.zacks.com/stock/news/2789089/penumbra-stock-up-post-q3-earnings-revenue-beat-margins-expand?cid=sm-stocktwits-2-2789089-teaser-20404&ADID=SYND_STOCKTWITS_TWEET_2_2789089_TEASER_20404

0 · Reply

BEATOFtheMARKET Nov. 9 at 10:47 PM

$PCTY $PDD $PDP $PEN $PEP

0 · Reply

Market Cap	12.12B
Revenue (ttm)	1.19B
Net Income (ttm)	14.01M
EPS (ttm)	N/A
PE Ratio	85.65
Forward PE	60.85
Profit Margin	1.17%
Debt to Equity Ratio	0.00

Volume	568,400
Avg Vol	489,380
Day's Range	N/A - N/A
Shares Out	39.16M
Stochastic %K	77%
Beta	0.71
Analysts	Strong Sell
Price Target	$336.29